专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5731206A Method and reagent system for isolation, identification and/or analysis of leukocytes from whole blood samples 失效
标题翻译：用于从全血样品中分离，鉴定和/或分析白细胞的方法和试剂系统
公开(公告)号：US5731206A
公开(公告)日：1998-03-24
申请号：US630868
申请日：1996-03-29
申请人： Stephen L. Ledis , Harold R. Crews , Timothy J. Fischer , Ted Sena
发明人： Stephen L. Ledis , Harold R. Crews , Timothy J. Fischer , Ted Sena
IPC分类号： G01N33/48 , G01N33/50 , G01N31/00
CPC分类号： G01N33/5094 , Y10T436/101666 , Y10T436/107497 , Y10T436/108331
摘要： A lytic reagent composition and a kit of a lytic reagent system are disclosed for the rapid isolation, identification and/or analysis of at least five subpopulations of leukocytes from a whole blood sample. The composition and system have application to any environment in which the study and/or analysis of the leukocyte fraction of whole blood requires their isolation in their native or near native state. The lytic reagent composition of this invention comprises saponin and a carboxylic acid of the formula RCOOH wherein R is H or a C.sub.1-3 aliphatic hydrocarbon radial optionally substituted by one or more carbonyl and/or hydroxy groups. The kit of a lytic reagent system comprises the lytic reagent composition and a quench reagent.
摘要翻译：公开了溶解试剂组合物和溶解试剂体系试剂盒，用于从全血样品中快速分离，鉴定和/或分析至少五个白细胞亚群。该组合物和系统适用于任何环境，其中全血白细胞分数的研究和/或分析需要其天然或接近天然状态的分离。本发明的溶解试剂组合物包含皂角苷和式RCOOH的羧酸，其中R是H或被一个或多个羰基和/或羟基取代的C 3-脂肪烃。裂解试剂系统的试剂盒包含裂解试剂组合物和淬灭试剂。

2. 发明授权

US5155044A Lysing reagent system for isolation, identification and/or analysis of leukocytes from whole blood samples 失效
标题翻译：用于从全血样品中分离，鉴定和/或分析白细胞的裂解试剂系统
公开(公告)号：US5155044A
公开(公告)日：1992-10-13
申请号：US808041
申请日：1991-12-12
申请人： Stephen L. Ledis , Harold R. Crews , Timothy J. Fischer , Ted Sena
发明人： Stephen L. Ledis , Harold R. Crews , Timothy J. Fischer , Ted Sena
IPC分类号： G01N33/50 , G01N33/569
CPC分类号： G01N33/5094 , G01N33/56972 , Y10T436/101666 , Y10T436/107497 , Y10T436/108331
摘要： A method and reagent system are disclosed for the rapid isolation, identification and/or analysis of leukocytes from a whole blood sample. The method and reagent system of this invention has application to any environment in which the study and/or analysis of the leukocyte fraction of whole blood requires their isolation in their native or near native state. One of the environments in which this invention can be used to advantage is in the performance of white cell differentiation on automated instrumentation designed for that purpose. In one of the preferred embodiments of this invention, the lytic reagent can contain a mixture of both formic and acetic acid, with the formic acid comprising the major component thereof and the acetic acid being present in only minor quantities, (if at all). This reagent system is used to selectively effect stromatolysis of red blood cells and create subtle modifications to the leukocyte population to enable their automated differentiation into five (5) sub-populations. The advantage and uniqueness of this reagent system is the surprising speed at which it is able to effect the foregoing objectives (generally less than 10 seconds at room temperature) and the ability to further differentiate the leukocyte population (notably, the granulocyte population). Following stromatolysis, a quenching agent is added to retard the reactivity of the lytic reagent system and, thus, inhibit any further dramatic changes to the leukocyte population. The treatment of the whole blood sample in the foregoing manner is further unique in that the leukocyte fraction of the sample has retained its characteristic immunochemical response.
摘要翻译：公开了用于从全血样品快速分离，鉴定和/或分析白细胞的方法和试剂系统。本发明的方法和试剂系统适用于其中全血白细胞分数的研究和/或分析需要在其天然或接近天然状态下分离的任何环境。本发明可用于有利的环境之一是在为此设计的自动化仪器上实现白细胞分化。在本发明的一个优选实施方案中，溶解剂可以含有甲酸和乙酸的混合物，其中甲酸包含其主要组分，乙酸仅以少量存在（如果有的话）。该试剂系统用于选择性地影响红细胞的间质分解，并对白细胞群体产生微妙的修饰，使其能够自动分化为五（5）个亚种群。该试剂系统的优点和独特之处在于其能够达到上述目的（通常在室温下通常小于10秒）以及进一步区分白细胞群体（特别是粒细胞群体）的能力的惊人速度。在层间裂解后，加入淬灭剂以延缓溶解试剂体系的反应性，从而抑制白细胞群体的任何进一步的剧烈变化。以上述方式对全血样品的处理是进一步的独特之处在于，样品的白细胞部分保持了其特有的免疫化学应答。

3. 发明申请

US20110163885A1 ADJUSTABLE THERAPEUTIC MATTRESS 审中-公开
标题翻译：可调理疗法
公开(公告)号：US20110163885A1
公开(公告)日：2011-07-07
申请号：US12833684
申请日：2010-07-09
申请人： Craig Poulos , Timothy J. Fischer , Joseph Immordino
发明人： Craig Poulos , Timothy J. Fischer , Joseph Immordino
IPC分类号： A47C27/10 , G08B21/00
CPC分类号： A61G7/05776 , A61G7/05707 , A61G7/05784
摘要： A therapeutic mattress is provided having a base layer, a plurality of separate air cell sections, an air source and a valve. The separate air cell sections have a plurality of fluidly interconnected air cell members extending vertically from a bottom wall. The air cell members of the air cell sections are independently moveable in a plurality of directions. The valve is fluidly connected to the plurality of separate air cell sections. The air source is connected to the valve to independently increase the air pressure in the air cell sections to a desired air pressure.
摘要翻译：提供一种治疗床垫，其具有基底层，多个单独的空气细胞部分，空气源和阀。单独的气囊部分具有从底壁垂直延伸的多个流体互连的气囊组件。气囊部分的空气囊部件可以在多个方向上独立地移动。阀流体地连接到多个单独的气囊部分。空气源连接到阀，以独立地将空气室部分中的空气压力增加到期望的空气压力。

4. 发明申请

US20090068690A1 METHODS FOR IDENTIFYING PATIENTS WITH AN INCREASED LIKELIHOOD OF HAVING OVARIAN CANCER AND COMPOSITIONS THEREFOR 审中-公开
标题翻译：用于鉴别具有OVARIAN癌症和其组合物的增加的患者的患者的方法
公开(公告)号：US20090068690A1
公开(公告)日：2009-03-12
申请号：US12261205
申请日：2008-10-30
申请人： Timothy J. Fischer , Douglas P. Malinowski , Qin He , Clark M. Whitehead , Robert L. Cheek , John W. Groelke
发明人： Timothy J. Fischer , Douglas P. Malinowski , Qin He , Clark M. Whitehead , Robert L. Cheek , John W. Groelke
IPC分类号： C12Q1/02 , C12Q1/00 , A61B5/00 , A61B5/055 , A61B10/00 , G01N33/53
CPC分类号： G01N33/57449
摘要： Screening methods for identifying patients with an increased likelihood of having ovarian cancer are provided. The screening methods involve the detection of expression of a plurality of biomarkers in a body sample, wherein overexpression of the biomarkers is indicative of an increased likelihood of having ovarian cancer. The screening methods may further comprise a two-step analysis. Biomarkers of interest include genes and proteins that are, for example, involved in defects in DNA replication/cell cycle control, cell growth and proliferation, escape from apoptosis, angiogenesis or lymphogenesis, or the mechanisms of cancer cell motility and invasion. In some aspects of the invention, expression of a biomarker is detected at the protein level using a biomarker-specific antibody or at the nucleic acid level using nucleic acid hybridization techniques. Methods for detecting ovarian cancer in patients are further disclosed herein. Kits for practicing the methods of the invention are further provided.
摘要翻译：提供了鉴定患卵巢癌可能性增加的筛查方法。筛选方法涉及检测体内样品中多种生物标志物的表达，其中生物标志物的过表达表明卵巢癌的可能性增加。筛选方法还可以包括两步分析。感兴趣的生物标志物包括例如参与DNA复制/细胞周期控制，细胞生长和增殖，逃避凋亡，血管生成或淋巴发生的缺陷或癌细胞运动和侵袭的机制的基因和蛋白质。在本发明的一些方面，使用生物标志物特异性抗体或在核酸水平使用核酸杂交技术在蛋白质水平上检测生物标志物的表达。本文进一步公开了患者卵巢癌检测方法。还提供了用于实施本发明的方法的试剂盒。

5. 发明申请

US20080254048A1 HE4 MONOCLONAL ANTIBODIES AND METHODS FOR THEIR USE 有权
标题翻译： HE4单克隆抗体及其使用方法
公开(公告)号：US20080254048A1
公开(公告)日：2008-10-16
申请号：US12044302
申请日：2008-03-07
申请人： Robert L. Cheek , Timothy J. Fischer , John W. Groelke
发明人： Robert L. Cheek , Timothy J. Fischer , John W. Groelke
IPC分类号： A61K39/00 , C07K16/18 , C12N5/06 , G01N33/574 , A61P37/00 , C12P21/04 , C07K14/00 , C07H21/00
CPC分类号： C07K16/3069 , C07K2317/34 , G01N33/57415 , G01N33/57449
摘要： Compositions and methods for diagnosing ovarian cancer in a patient and for identifying patients with an increased likelihood of having ovarian cancer are provided. The compositions include novel monoclonal antibodies, and variants and fragments thereof, that specifically bind to HE4. Monoclonal antibodies having the binding characteristics of an HE4 antibody of the invention are further provided. Hybridoma cell lines that produce an HE4 monoclonal antibody of the invention are also disclosed herein. The compositions find use in diagnostic methods as well as in screening methods for identifying patients having an increased likelihood of having ovarian cancer. Kits comprising one or more of the disclosed HE4 monoclonal antibodies and for practicing the methods of the invention are further provided. Polypeptides comprising the amino acid sequence for an HE4 epitope and methods of using these polypeptides in the production of antibodies are also encompassed by the present invention.
摘要翻译：提供了一种用于诊断患者卵巢癌和用于鉴定患卵巢癌可能性增加的患者的组合物和方法。组合物包括特异性结合HE4的新型单克隆抗体及其变体和片段。进一步提供具有本发明的HE4抗体的结合特性的单克隆抗体。本文还公开了产生本发明的HE4单克隆抗体的杂交瘤细胞系。该组合物用于诊断方法以及用于鉴定具有增加卵巢癌可能性的患者的筛选方法。还提供了包含一种或多种所公开的HE4单克隆抗体和用于实施本发明的方法的试剂盒。包含HE4表位的氨基酸序列的多肽和在产生抗体中使用这些多肽的方法也包括在本发明中。

6. 发明授权

US07179612B2 Method for detecting a lipoprotein-acute phase protein complex and predicting an increased risk of system failure or mortality 有权
标题翻译：用于检测脂蛋白 - 急性期蛋白复合物并预测系统衰竭或死亡风险增加的方法
公开(公告)号：US07179612B2
公开(公告)日：2007-02-20
申请号：US10019087
申请日：2001-06-08
申请人： Timothy J. Fischer , Colin Downey , Mike Nesheim , John A. Samis , Liliana Tejidor , Cheng-Hock Toh , John B. Walker
发明人： Timothy J. Fischer , Colin Downey , Mike Nesheim , John A. Samis , Liliana Tejidor , Cheng-Hock Toh , John B. Walker
IPC分类号： G01N33/536 , G01N33/537 , G01N33/539 , G01N55/564 , C12Q1/60
CPC分类号： G01N33/86 , G01N33/92 , G01N2800/044 , G01N2800/52
摘要： A method for diagnosing a condition of a patient involves the steps of (a) adding one or more reagents to a test sample from a patient, the test samples comprising at least part of a blood sample from the patient, in order to cause formation of a complex comprising at least one acute phase protein and at least one human lipoprotein, while causing substantially no fiber polymerization; (b) measuring the formation of the complex over time so as to derive a time-dependent measurement profile, and (c) determining a slope and/or total change in the time-dependent measurement profile, so as to diagnose a condition of the patient. A greater formation of the complex is correlated to increased probability of death of the patient.
摘要翻译：用于诊断患者状况的方法包括以下步骤：（a）将一种或多种试剂添加到来自患者的测试样品中，所述测试样品包含来自患者的血液样品的至少一部分，以便形成包含至少一种急性期蛋白质和至少一种人类脂蛋白的复合物，同时基本上不引起纤维聚合; （b）随着时间的推移测量复合物的形成，以便导出时间相关的测量曲线，以及（c）确定时间依赖性测量曲线的斜率和/或总变化，以诊断患者。复合物的更大形成与患者死亡概率增加相关。

7. 发明授权

US06898532B1 Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample 失效
标题翻译：用于预测患者样品中止血功能障碍的存在的方法和装置
公开(公告)号：US06898532B1
公开(公告)日：2005-05-24
申请号：US10377228
申请日：2003-02-28
申请人： Cheng Hock Toh , Colin Downey , Timothy J. Fischer
发明人： Cheng Hock Toh , Colin Downey , Timothy J. Fischer
IPC分类号： G01N33/49 , G01N33/86 , G06F19/00 , G01N21/00
CPC分类号： G01N33/86 , G01N33/4905 , G06F19/00 , G16H10/40 , G16H15/00 , G16H50/50 , Y02A90/26
摘要： A method is disclosed for predicting the presence of haemostatic dysfunction. At least one time-dependent measurement on an unknown sample is performed and a respective property of the sample is measured over time so as to derive a time-dependent measurement profile. One or more predictor variables, including initial slope, are defined which sufficiently define the data of the time-dependent measurement profile. A model is then derived that represents the relationship between the abnormality and the set of predictor variables. Subsequently, the model is utilized to predict haemostatic dysfunction, such as septicemia or disseminated intravascular coagulation (DIC).
摘要翻译：公开了一种用于预测止血功能障碍的存在的方法。对未知样品进行至少一次时间依赖性测量，并随时间测量样品的相应性质，从而导出时间依赖性测量分布。定义一个或多个预测变量，包括初始斜率，其充分地定义时间依赖性测量分布的数据。然后导出代表异常和预测变量集之间的关系的模型。随后，该模型用于预测止血功能障碍，例如败血病或弥散性血管内凝血（DIC）。

8. 发明授权

US06429017B1 Method for predicting the presence of haemostatic dysfunction in a patient sample 有权
标题翻译：用于预测患者样品中止血功能障碍的存在的方法
公开(公告)号：US06429017B1
公开(公告)日：2002-08-06
申请号：US09372954
申请日：1999-08-12
申请人： Cheng Hock Toh , Colin Downey , Timothy J. Fischer
发明人： Cheng Hock Toh , Colin Downey , Timothy J. Fischer
IPC分类号： G01N3386
CPC分类号： G01N33/4905 , G01N30/96 , G01N33/86
摘要： A method which may be used to determine haemostatic dysfunction in a patient is carried out by (a) adding a reagent to a test sample, wherein the test sample includes at least a component of a blood sample from a patient; and then (b) measuring the formation of a precipitate due to the reaction of the test sample and the reagent, over time so as to derive a time-dependent measurement profile, the reagent forming a precipitate in the test sample without causing substantial fibrin polymerization.
摘要翻译：可以用于确定患者止血功能障碍的方法是通过（a）向试验样品中加入试剂，其中所述测试样品至少包括来自患者的血样的成分; 然后（b）随着时间的推移测量由于测试样品和试剂的反应而产生的沉淀物的形成，从而导出时间依赖性测量曲线，试剂在测试样品中形成沉淀物而不引起显着的纤维蛋白聚合。

9. 发明授权

US06321164B1 Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade 失效
标题翻译：用于预测凝血级联中一种或多种蛋白质异常水平的存在的方法和装置
公开(公告)号：US06321164B1
公开(公告)日：2001-11-20
申请号：US09001647
申请日：1997-12-31
申请人： Paul Braun , Thomas B. Givens , Timothy J. Fischer
发明人： Paul Braun , Thomas B. Givens , Timothy J. Fischer
IPC分类号： G01N2100
CPC分类号： G01N33/86 , G01N33/4905 , G01N2800/226 , G01N2800/385 , G06F19/00 , G16H50/20
摘要： A method is disclosed for predicting the presence of an abnormal level of one or more proteins in the clotting cascade from at least one time-dependent measurement profile. At least one time-dependent measurement on an unknown sample is performed and a respective property of said sample is measured over time so as to derive a time-dependent measurement profile. A set of a plurality of predictor variables are defined which sufficiently define the data of the time-dependent measurement profile. A model is then derived that represents the relationship between the abnormality and the set of predictor variables. Subsequently, the model is utilized to predict which protein or proteins in the clotting cascade are at an abnormal level, with the prediction being a more informative prediction than clot time alone.
摘要翻译：公开了一种用于从至少一个时间依赖的测量轮廓预测凝血级联中的一种或多种蛋白质的异常水平的存在的方法。对未知样品进行至少一次时间依赖性测量，并随时间测量所述样品的相应性质，以便导出时间依赖性测量分布。定义了一组多个预测变量，其充分地定义了时间依赖性测量轮廓的数据。然后导出代表异常和预测变量集之间的关系的模型。随后，该模型用于预测凝血级联中的哪些蛋白质或蛋白质处于异常水平，预测比单独凝血时间更有信息。

10. 发明授权

US6101449A Method for predicting the presence of congenital and therapeutic conditions from coagulation screening assays 失效
标题翻译：用于从凝血筛选测定法预测先天性和治疗条件的存在的方法
公开(公告)号：US6101449A
公开(公告)日：2000-08-08
申请号：US859773
申请日：1997-05-21
申请人： Thomas B. Givens , Paul Braun , Timothy J. Fischer
发明人： Thomas B. Givens , Paul Braun , Timothy J. Fischer
IPC分类号： G01N33/48 , C07K16/18 , G01N33/49 , G01N33/50 , G01N33/86 , G01N35/00 , G06F15/18 , G06F19/00 , G06N3/00 , G06Q50/00 , G01N21/00
CPC分类号： G01N33/4905 , C07K16/18 , G01N33/86 , G01N35/00 , G06F19/3437 , G06F19/366 , G01N2800/226 , G01N2800/385 , G06F19/322 , G06F19/345
摘要： A method and apparatus are disclosed for predicting the presence of at least one congenital or acquired imbalances or therapeutic condition associated with thrombosis/hemostasis from at least one time-dependent measurement profile. At least one time-dependent measurement in a sample is performed and a respective property of sample is measured over time so as to derive a time-dependent measurement profile. A set of a plurality of predictor variables are defined which sufficiently define the data of the time-dependent measurement profile. A model is then derived that represents the relationship between the congenital or acquired imbalance or therapeutic condition, and the set of predictor variables. Subsequently, the model is utilized to predict the existence of the congenital or acquired imbalance or therapeutic condition in a sample.
摘要翻译：公开了一种用于从至少一个时间依赖的测量轮廓预测与血栓形成/止血有关的至少一种先天性或获得性不平衡或治疗条件的存在的方法和装置。在样品中进行至少一次时间依赖性测量，并随时间测量样品的相应性质，从而导出时间依赖性测量曲线。定义了一组多个预测变量，其充分地定义了时间依赖性测量轮廓的数据。然后导出代表先天性或获得性不平衡或治疗条件之间的关系的模型以及预测变量的集合。随后，该模型用于预测样品中先天性或获得性不平衡或治疗条件的存在。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式